Lurbinectedin

Small Cell Carcinoma

SystImmune Inc.Small moleculePhase 3Active

BB

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 95/ 100

Competitive context

17 Active assets in the Small Cell Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Nogitecan National Cancer Institute (NCI)	Phase 2	BB
Cis-Diamminedichloroplatinum Ii EpicentRx, Inc.	Phase 2	BB
Vinorelbine Ditartrate EpicentRx, Inc.	Phase 2	BB
Etoposide SystImmune Inc.	Phase 3	BB
Pembrolizumab Thomas Jefferson University	Phase 2	BB

View all 30 →

Same molecule, other indications

Lurbinectedin is also rated in:

small cell lung carcinomaActive

BB

Indicative · Phase 3

66 / 100

lung carcinomaActive

B

Indicative · Phase 3

60 / 100

neuroendocrine carcinomaActive

B

Indicative · Phase 2

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.